Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06651600 dose-ranging and extension study in active non-segmental vitiligo
2018-001271-20Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing PF-06651600 dose-ranging, Placebo and Extension PF-06651600 or PF-06700841 (3 arms). Primary endpoint: Percent change from baseline in facial-VASI at Week 24. Started Apr 2019; status: completed.
02
Drugs
ritlecitinib tosilatebrepocitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2018-001271-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001271-20.